Targeting specific cancer pathways in prostate cancer without PTEN
Combined inhibition of ATR and p110β as Therapy in PTEN-deficient Prostate Cancer
['FUNDING_R21'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-11042240
This study is exploring a new treatment for prostate cancer that doesn't have the PTEN gene, by combining two specific therapies to see if they can work better together to shrink tumors and help patients feel better.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-11042240 on ClinicalTrials.gov |
What this research studies
This research investigates a new treatment approach for prostate cancer that lacks the PTEN gene, which is often associated with aggressive disease. The study aims to combine the inhibition of two key proteins, ATR and p110β, to enhance the effectiveness of cancer therapies. By using advanced mouse models that mimic human prostate cancer, researchers will assess how this combination therapy can reduce tumor growth and improve patient outcomes. The goal is to develop a novel strategy that could potentially overcome resistance to existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer that is PTEN-deficient.
Not a fit: Patients with prostate cancer that does not involve PTEN mutations or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with advanced prostate cancer, particularly those who have not responded to standard treatments.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting the PI3K pathway in cancer treatment, indicating potential for success in this novel combination therapy.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DING, LIYA — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: DING, LIYA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer